Cala in the news

January 9, 2024

Cala Announces Data from Multiple Clinical Studies Demonstrating Effective Outcomes of Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy in Essential Tremor (ET) Patients

June 14, 2023

Cala Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

April 19, 2023

Cala Introduces Next Generation System and Accelerates Leadership in Bioelectronic Medicine

March 23, 2023

Cala TAPS Therapy for Essential Tremor Patients Improves Outcomes in a New Randomized Controlled Trial

October 11, 2022

Cala Receives Pricing from CMS for Cala TAPS Therapy to Expand Medicare Patient Access

September 27, 2022

Real World Evidence of Cala TAPS Therapy Further Supports Long-Term Safety and Efficacy of its Treatment for Essential Tremor

May 18, 2022

Research Confirms Patients with Essential Tremor and Parkinson’s Disease Have Higher Comorbidities and Costs

May 18, 2022

Cala Partners with SK Biopharmaceuticals to Fuel Innovation in Neurology

April 4, 2022

New Research Presented at AAN Demonstrates Burden Associated with Essential Tremor and the Unmet Patient Need

March 28, 2022

Cala Health Expands Leadership Team to Fuel Growth and Continued Innovation

March 1, 2022

Cala Health Is Building Momentum By Expanding Affordable Access for Patients with Essential Tremor

November 16, 2021

Cala Health Raises $77M to Expand Patient Access and Fuel Continued Innovation

September 14, 2021

Cala Trio is a Rising Standard of Care for the Treatment of Essential Tremor through Clinical Research and Industry Guidelines

June 17, 2021

Cala Health and University of California, San Francisco Announce Partnership to Develop Next-Generation, Smart Neuromodulation Therapies

June 17, 2021

Cala Health Announces Expansion of Executive Team with Steve Higa and Greg Schulte

May 20, 2021

Cala Health Reports New Data Presented at ISPOR, Highlighting Essential Tremor (ET)-Related Comorbidities and Economic Burden

April 15, 2021

Cala Health Reports New Data Demonstrating How Cala Trio™ Enables a More Frequent Assessment of Hand Tremor Compared with In-Person Assessments in Patients with Essential Tremor and Supports Feasibility of Telemedicine Approaches for Essential Tremor Management

November 16, 2020

Cala Health Reports New Data Demonstrating Increasing Prevalence of Essential Tremor (ET) and High Rates of Depression and Anxiety in Patients with ET

October 22, 2020

Cala Health Receives FDA Breakthrough Device Designation for Cala Trio™ Therapy to Treat Action Tremors in Parkinson’s Disease

September 14, 2020

First Real-World Evidence Demonstrates Cala Trio’s Effectiveness in Essential Tremor with Individually Calibrated, Non-Invasive Stimulation

August 17, 2020

Cala Health Announces Continued Growth and Momentum with Clinical, Product Development, and Management Milestones to Support Cala Trio Therapy for the Treatment of Essential Tremor

September 22, 2019

Cala Health Announces Positive Topline Data from Landmark PROSPECT Study for Essential Tremor (ET)

September 3, 2019

Cala Health Names Veteran Leader Renee Ryan as Chief Executive Officer

June 12, 2019

Researcher Developing Nerve Stimulation Device

May 20, 2019

Cala Health Raises $50 Million Series C Funding

March 11, 2019

Cala Health Licenses Innovative Technology from Partners Healthcare to Develop and Deliver Novel Therapies for Patients with Chronic Disease

February 20, 2019

Cala Health participates in Industry and Academic Forum resulting in the Initial Guiding Principles on Ethics in Digital Health

December 16, 2018

Cala Health Enrolls First Patients in Landmark PROSPECT Study for Essential Tremor

April 25, 2018

Cala Health Receives FDA Clearance for Cala ONE, A Neuroperipheral Therapy for Essential Tremor

April 16, 2018

Noninvasive Neuromodulation in Essential Tremor Demonstrates Relief in a Sham-Controlled Pilot Trial

November 7, 2017

Exponential Medicine 2017: Delivering Electricity as Medicine

November 1, 2017

Cala Health’s CEO Kate Rosenbluth selected as a Hive Innovator for 2017 by TEDMED